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Hematotoxicity in individuals genetically deficient in glucose-6-phosphate dehydrogenase (G6PD) activity is the major limita-
tion of primaquine (PQ), the only antimalarial drug in clinical use for treatment of relapsing Plasmodium vivaxmalaria. PQ is
currently clinically used in its racemic form. A scalable procedure was developed to resolve racemic PQ, thus providing pure
enantiomers for the first time for detailed preclinical evaluation and potentially for clinical use. These enantiomers were com-
pared for antiparasitic activity using several mouse models and also for general and hematological toxicities in mice and dogs.
()-(S)-PQ showed better suppressive and causal prophylactic activity than ()-(R)-PQ in mice infected with Plasmodium ber-
ghei. Similarly, ()-(S)-PQ was a more potent suppressive agent than ()-(R)-PQ in a mouse model of Pneumocystis carinii
pneumonia. However, at higher doses, ()-(S)-PQ also showedmore systemic toxicity for mice. In beagle dogs, ()-(S)-PQ
caused more methemoglobinemia and was toxic at 5 mg/kg of body weight/day given orally for 3 days, while ()-(R)-PQ was
well tolerated. In a novel mouse model of hemolytic anemia associated with human G6PD deficiency, it was also demonstrated
that ()-(R)-PQ was less hemolytic than ()-(S)-PQ for the G6PD-deficient human red cells engrafted in the NOD-SCIDmice.
All these data suggest that while ()-(S)-PQ shows greater potency in terms of antiparasitic efficacy in rodents, it is also more
hematotoxic than ()-(R)-PQ inmice and dogs. Activity and toxicity differences of PQ enantiomers in different species can be
attributed to their different pharmacokinetic andmetabolic profiles. Taken together, these studies suggest that ()-(R)-PQmay
have a better safety margin than the racemate in human.
The 8-aminoquinolines (8-AQs) are a drug class showing broadand potent antiparasitic activity (1). They are the only drugs
known to kill the tissue schizont form (hypnozoite) of the para-
sites causing relapsing malaria and further have the capacity to
block infection by preventingmosquito-injected sporozoites from
establishing infection in the liver. They also have gametocidal ac-
tivity and can interrupt disease transmission from mosquitos
feeding on an infected patient and subsequently feeding on non-
infected persons. Consequently, any strategy for eradication of
malaria will likely need to incorporate utilization of an 8-AQ (1).
Primaquine (PQ), the only clinically approved 8-AQ, is currently
used for the treatment of relapsingmalaria (2, 3) and as a prophy-
lactic agent against all major forms of human malaria (4). This
drug is ineffective against blood-stage malaria parasites at the ef-
fective antirelapse doses (3). In addition, PQ is effective in com-
bination with clindamycin for the treatment and prophylaxis of
Pneumocystis jirovecii (formerly Pneumocystis carinii) pneumonia
in immunosuppressed patients (5). PQ has also shown significant
activity against other disease-causing parasites, such as Trypano-
soma (6) and Leishmania (7). The major limitation to broad clin-
ical use of PQ and other 8-AQ antiparasitic agents is that they
cause methemoglobinemia (8, 9) and hemolytic anemia (9, 10) in
individuals genetically deficient in glucose-6-phosphate dehydro-
genase (G6PD) activity.
PQ is clinically used in its racemic form, a mixture of two
enantiomers. We previously reported (11) different therapeutic
indices for individual enantiomers of another member of this
class, 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-
5-[3,4-dichlorophenoxy]quinoline. With this 8-AQ analog, the
()-R enantiomer, NPC1161B, had a better therapeutic index
than the ()-S enantiomer, NPC1161A, or the racemate,
NPC1161C (Fig. 1). Limited previous results comparing the indi-
vidual enantiomers of PQ, made available by a challenging and
expensive resolution of racemic PQ (12), also suggested different
therapeutic indices and rate of metabolism. Schmidt et al. (13)
reported that ()-(S)-PQ, ()-(R)-PQ, and racemic PQ (Fig. 1)
were equally curative against sporozoite-induced Plasmodium
cynomolgi infections in rhesus monkeys, the only experimental
model for relapsing malaria. They also reported that ()-(S)-PQ
was approximately 4 times as toxic (acute lethality) as the ()
form in mice but, unexpectedly, the () form was 3 to 5 times as
toxic as the () form and at least twice as toxic as the racemate in
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rhesus monkeys (13). In an in vitro tissue schizontocidal assay
with mouse hepatocytes, the () isomer was found to be equally
active and slightly less cytotoxic than ()-PQ (14). On the other
hand ()-PQ was less active and less cytotoxic than ()-PQ. In
another study, ()-PQ produced more methemoglobin and
caused less membrane leakiness in human erythrocytes, whereas
with the () isomer, the opposite was observed (15). Nicholl et al.
(16) reported similar rates of clearance for individual enantiomers
of PQ in an isolated perfused rat liver preparation but amore facile
conversion of the ()-PQ to the carboxy metabolite, which was
thought to be inactive. In previous studies, we observed no selec-
tivity for metabolism of the () and () isomers in a rat liver
microsomal preparation, but microsomes with themitochondrial
fraction showed amarkedpreference for the conversion of the ()
isomer to the carboxyprimaquine metabolite (17). When racemic
PQ was administered to laboratory rats, a majority of residual PQ
excreted in the urinewas the () isomer (17). Inmice treatedwith
racemic PQ, the two enantiomers exhibited similar plasma PK
profiles (maximum concentration in serum [Cmax] and time to
maximumconcentration in serum [Tmax]) (18). However, plasma
()-PQ level declined faster than ()-PQ. A pronounced differ-
ence was noted in the plasma PK profile of the enantiomers of
carboxy-PQ (cPQ), the major PQ metabolite. The Cmax for ()-
cPQ was more than 17-fold higher than that for ()-cPQ (18).
With the disparate toxicity profiles of PQ enantiomers in dif-
ferent species and given the steep dose response curve for PQ in
humans, Schmidt and coworkers (13) concluded, 35 years ago,
that the available data warranted a separate clinical evaluation of
PQ enantiomers. However, so far no work has been done to eval-
uate individual PQ enantiomers in humans. Amajor impediment
to such clinical evaluation was the lack of availability of PQ enan-
tiomers of cGMP quality. The cumbersome nature of the method
previously used to resolve PQ (12) would not provide the enan-
tiomers economically nor scale appropriately for cGMP prepara-
tion. To overcome this limitation and to provide PQ enantiomers
economically, we have developed a simple procedure to resolve
racemic PQ on a large scale. With quantities of the individual
enantiomers in hand, we evaluated more extensively the compar-
ative antiparasitic activities and toxicities of the enantiomers in
mice and dogs. Evaluations of antimalarial efficacy, pharmacoki-
netics, and toxicity in nonhuman primates also have been com-
pleted (D. Saunders, P. Vanachayangkul, P. Khemawoot, R.
Imerbsin, R. Siripokasupkul, B. L. Tekwani, A. Sampath, N. P. D.
Nanayakkara, C. Ohrt, P. Teja-Isavadharm, and L. A.Walker, un-
published data). In this article, we extend earlier evidence suggest-
ingmarked species differences in PQ enantiomer profiles and em-
phasize that there is warrant for comparing PQ enantiomers in
humans with respect to hematological liability in G6PD-deficient
subjects and antimalarial efficacy.
MATERIALS AND METHODS
Materials and chemicals. Primaquine diphosphate and other reagents
were purchased from Sigma-Aldrich (St. Louis, MO). Solvents (certified
American Chemical Society [ACS] and high-pressure liquid chromatog-
raphy [HPLC] grade) were purchased from Fisher Scientific (Atlanta,
GA).
Resolution of racemic primaquine. Experimental details for the res-
olution of racemic primaquine are provided in the supplementalmaterial.
Crystallographic data for NPC1161A (R)-()-phenylethylurea de-
rivative. Experimental details, crystallographic data, and the ORTEP
(Oak Ridge thermal ellipsoid plot) diagram for this compound are pro-
vided in the supplemental material.
Antimalarial blood schizontocidal activity in mice. A suppressive-
curativePlasmodiumbergheimousemodel was employed for in vivo blood
schizonticidal antimalarial efficacy evaluation. The in vivo antimalarial
activity was determined for mice infected with Plasmodium berghei
(NK-65 strain) according to Peters’ 4-day suppressive test, which has been
modified to a 3-day treatment schedule.Malemice (SwissWebster strain)
weighing 18 to 20 g were intraperitoneally inoculated with 2 107 para-
sitized red blood cells obtained from a highly infected donormouse.Mice
were divided into different groups, with 5 mice in each group. The solu-
tions of PQ (racemate and the pure enantiomers) were prepared inNano-
pure sterile water and administered orally (p.o.) through gavage to the
mice about 2 h after the infection (day 0). Themicewere treated once daily
for three consecutive days (days 0 to 2). A control group of mice was
treated with an equal volume of vehicle, while another control group was
treated with the standard antimalarial drug chloroquine. The mice were
closely observed after every dose for any apparent signs of toxicity, and the
body weights were recorded once daily. Blood smears were prepared on
different days (till day 28 postinfection) by tail snip, stained with Giemsa
stain, and evaluated under amicroscope for determination of parasitemia.
Mice without parasitemia after day 28 postinfection were considered
cured. These groups of animals were also tested to determine levels of
hemoglobin and methemoglobin. For determination of hemoglobin and
methemoglobin, about 50 l of blood was collected with tail snip. The
blood was diluted 1:5 with phosphate-buffered saline supplemented with
glucose containing EDTA. The levels of hemoglobin and methemoglobin
were evaluated using an IL-682 co-oximeter precalibrated with rodent
blood.
Antimalarial causal prophylaxis in mice. ICR female mice were each
inoculated with 80,000 to 100,000 sporozoites (in 0.1 ml of phosphate-
buffered saline and 5%bovine serum albumin) of the Plasmodium berghei
ANKA strain. The sporozoites were isolated by dissection from Anopheles
dirus mosquitoes fed on donor mice. On days 1, 0, and 1, ()- and
()-PQ were administered at doses ranging from 5 to 40 and 10 to 160
mg/kg/day, respectively (n 5 for each dose level). Racemic primaquine
was administered at 25 mg/kg/day. Drug administration was performed
once daily for 3 days using a vehicle of 0.5% hydroxyethylcellulose–0.1%
Tween 80 (HECT) and delivered orally via a 20-gauge plastic oral feeding
tube. Once inoculated with active sporozoites, mice develop parasitemia
(microscopic examination) on the 4th day; all untreated mice die (or
reach the study endpoint of 5% parasitemia, requiring euthanasia) on
days 6 to 8. Administration of antimalarial drugs with causal prophylactic
activity will delay (at low doses) or prevent altogether (at effective doses)
FIG 1 Structures of primaquine, NPC1161C, and their enantiomers.
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the rise in parasitemia. Successful causal prophylaxis is determined by
survival to day 31 postinoculation.
Activity against Pneumocystis carinii infection in mice (19). Female
BALB/c mice free of Pneumocystis, 6 to 8 weeks of age (Harlan Sprague
Dawley) were immunosuppressed by the administration in drinking wa-
ter of 1.2 mg/ml dexamethasone. After 4 days, animals were transtrache-
ally inoculated with 106 P. carinii organisms and were continued on im-
munosuppressive agents. At 4 weeks postinoculation, treatment was
begun and continued for 3 weeks. There were 10 mice in each group. Test
compounds [()-PQ, ()-PQ, or racemic PQ] were administered in
drinking water to deliver doses approximating 2, 5, or 10 mg/kg/day. The
drugs were prepared fresh daily, and consumption for each group was
monitored and adjusted as needed to ensure proper dosing. A group of
untreated animals served as a negative control, and positive-control
groups included trimethoprim (TMP)-sulfamethoxazole (SMX) (50 and
250mg/kg/day) andNPC1161B (10) (0.25-mg/kg/day) treatments. At the
end of 3 weeks of therapy, animals were anesthetized and exsanguinated
by cardiac puncture. Lungs were removed, and representative portions of
lower lobes were used to make impression smears. Four impression
smears, fixed in methanol, were evaluated for the presence of P. carinii by
staining with Giemsa stain. Slides were blinded as to treatment and exam-
ined microscopically by two experienced individuals. The ratios of the
number of animals cured (no detectable infection) to the total number
treated were recorded.
Hematological toxicity for G6PD-deficient human red cells in NOD-
SCID mice. Eight- to nine-week-old female NOD.CB17-Prkdcscid/J mice
(NOD-SCID mice) (Jackson Laboratories, Bar Harbor, ME) were trans-
fused intraperitoneally (i.p.) with African variant G6PD-deficient human
red blood cells (huRBC) for 14 days as described previously (20).
Approximately 5 l of blood was analyzed for the presence of huRBC
using phycoerythrin (PE)-conjugated anti-human CD235a antibody
(Abcam, Cambridge, MA), and cells were acquired on a Guava Easy-
Cyte Plus flow cytometer (Millipore, Billerica, MA). Analysis of the
flow data was done using the FloJo software program (TreeStar, Inc.,
Ashland, OR). Mice with peripheral huRBC levels greater than 60%
were randomized for drug treatment, with 4 to 5 mice per group as-
signed. PQ or enantiomers were resuspended in PBS and given i.p.
twice daily for 7 days.
Comparison of PQ enantiomer toxicity in beagle dogs. Six female
beagle dogs (3/group) were assigned to the study and were dosed once
daily for up to 3 days with 4.86 mg/kg/day of either ()-PQ diphosphate
or ()-PQ diphosphate; dosage was calculated as the free base. The final
(4th) day of dosing was not performed due to the deteriorating health of
the dogs dosed with ()-PQ. Parameters evaluated included mortality,
clinical observations, body weights, serum chemistry, and hematology.
Gross necropsies were also performed on animals sacrificed in a mori-
bund state; animals surviving to the end of the study were returned to the
stock colony.
RESULTS
Preparation and spectral characterization of PQ enantiomers.
The preparation of PQ enantiomers and their characterization are
summarized in Fig. S1 in the supplemental material. PQ phthal-
imide, which is an intermediate in the synthesis of PQ (or can be
readily prepared by treating commercially available PQ with
phthalic anhydride), was resolved by fractional crystallization
with ()- and ()-tartaric acid. This procedure can be imple-
mented on a large scale to generate large amounts of PQ enan-
tiomers economically and is amenable for incorporation into a
cGMP manufacturing process.
Comparative antimalarial blood schizonticidal activity in
mice. Though at clinically used doses PQ has little or no blood
schizonticidal activity in humans, with higher doses in rodent
models, suppression of parasitemia was readily observable. Eval-
uation of racemic PQ and its enantiomers against Plasmodium
berghei in a rodent model showed that they were partially curative
at 100 mg/kg/day (Table 1). PQ racemate and the enantiomers
were not curative at doses of 33.3 and 11.1 mg/kg/day. Even
though no conclusions could be made on relative potencies of the
racemate and ()-PQ based on the parasitemia suppression data
at the dose of 11.1 mg/kg/day, comparison of these data at this
dose for day 5 and day 7 indicated that ()-PQ was less suppres-
sive than ()-PQ (P values 0.0098 and 0.0136, respectively) or the
racemate (P values 0.0014 and 0.3005, respectively). At the dose of
33.3mg/kg/day, both the racemate and ()-PQhad total suppres-
sion of parasitemia on days 5 and 7, whereas ()-PQ showed only
partial suppression. Racemic and ()-PQ showed some signs of
toxicity at the 100-mg/kg dose. The mice treated with both race-
mic and ()-PQ showed less mobility and grooming than the
animals in the control, chloroquine-, and ()-PQ-treated groups.
The mice treated with ()-PQ also underwent a reversible loss in
body weight on days 4 to 6 posttreatment (Fig. 2). The hemato-
TABLE 1 Suppressive antimalarial activities of primaquine enantiomers in mice
Compound
Dose, mg/kg/day
(3 days)
% parasitemia suppressiona
Survivalb; day(s) of death (MST)c
No. cured/no.
treateddDay 5 Day 7
Primaquine 11.1 97.47 4.47 54.91 39.25 3/5; 21, 21, 28, 28, 28 (25.2 3.8) 0/5
33.3 100 100 5/5; (28) 0/5
100 100 100 5/5; (28) 4/5
()-Primaquine 11.1 79.85 20.65 70.64 13.96 0/5; 15, 18, 18, 21, 21 (18.6 2.5) 0/5
33.3 100 100 4/5; 24, 28, 28, 28, 28 (27.2 1.8) 0/5
100 100 100 5/5; (28) 2/5
()-Primaquine 11.1 13.34 39.01 32.30 23.35 0/5; 12, 14, 14, 18, 18 (15.2 2.7) 0/5
33.3 90.35 13.89 46.04 37.02 4/5; 8,28,28,28,28 (24.0 8.9) 0/5
100 100 100 5/5; (28) 2/5
Vehicle 0/5; 5/14/17/17/17 (14.0 5.2) 0/5
a Percent suppression of parasitemia was calculated by considering the mean parasitemia in the vehicle control to be 100%. Values are means SD of results for five animals.
b Number of animals that survived day 28/total animals in group (day of death postinfection).
c MST, mean survival time (days). Values are means SD of results for five animals.
d Number of mice without parasitemia (cured) till day 28 postinfection.
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logical parameters, namely, total hemoglobin and methemoglo-
bin levels, were not significantly altered in the mice following
treatment with ()-PQor either of the PQ enantiomers (Table 2).
The hematological toxicities of racemic PQ and the enantiomers
were evaluated separately in beagle dogs and also using the hu-
manized SCID mouse model.
Comparative antimalarial causal prophylaxis in mice. The
difference in antimalarial potency between the two enantiomers
was much more prominent for the developing liver stages in the
causal prophylaxis model. In this assay, ()-PQ protected 50% of
animals at a dose of 10 mg/kg/day for 3 days and 100% of animals
at a dose of 25 mg/kg/day, whereas ()-PQ conferred 100% pro-
tection only at 80 mg/kg/day (Fig. 3). Two animals treated with
()-PQ at dose of 40 mg/kg/day and one animal treated with
()-PQ at a dose of 160mg/kg/day died due to toxicity, indicating
that the acute systemic toxicity of ()-PQ is also greater than that
of ()-PQ for this species. At a dose of 25mg/kg/day, racemic PQ
conferred 100% protection. The data were analyzed in the Graph-
Pad Prism software program by sigmoidal emax nonlinear regres-
sion, and the 80% effective doses (ED80s) are as follows: ()-PQ
ED80  10.5 mg/kg/day for 3 days; ()-PQ ED80  63.7 mg/kg/
day for 3 days. The racemic PQ dose response was not determined
in this study, but in a previous study in our lab (AFRIMS), 20
mg/kg/day for 3 days provided effective prophylaxis for 80%of the
mice (M. Gettayacamin and A. Tungtaeng, unpublished data).
Also, in 19 different experiments using 25mg/kg/day for 3 days for
racemic PQ as a positive control (n 5 in each experiment), the
25-mg/kg dose was at or above the ED80 (80% survival in 3/19
experiments and 100% survival in 16/19 experiments) (Gettaya-
camin and Tungtaeng, unpublished). Thus, the ED80 for racemic
PQ is estimated at between 20 and 25 mg/kg, likely closer to 20;
since half of this dose is an ED80 for ()-PQ, these data nicely
reconcile and suggest that all of the activity of the racemate in
standard effective rodent doses of racemic PQ resides in the ()
enantiomer.
Comparative antipneumocystis activity in mice. When the
enantiomers were evaluated using amousemodel for suppression
ofPneumocystispneumonia infection, it was also observed that the
()-PQ enantiomer is more active (Table 3). At a dose of 10
FIG 2 Effect of treatment with PQ enantiomers on total body weight of Plas-
modium berghei-infected mice. The P. berghei-infected mice were treated once
daily for 3 days (days 0, 1, and 2) (2 h after infection) with racemic PQ and PQ
enantiomers. Chloroquinewas tested as a control drug. The results shownhere
are for the 100-mg/kg dose. The lower doses did not show any effect on total
body weights. Each point shows mean  SD values from 5 animals in each
group.
TABLE 2 Effects of treatment of Plasmodium berghei-infected mice with
primaquine enantiomers on methemoglobin levelsa
Group %Methemoglobin P value
Vehicle control 0.82 0.65
Chloroquine 0.78 0.22 0.9 (NS)
()-Primaquine 1.22 0.31 0.25 (NS)
()-Primaquine 1.12 0.25 0.36 (NS)
()-Primaquine 0.66 0.51 0.68 (NS)
a The P. berghei-infected mice were treated once daily for 3 days (days 0, 1, and 2) (2 h
after infection) with racemic PQ and PQ enantiomers. Chloroquine was tested as a
control drug. The results shown here are for the 100-mg/kg dose. Blood was collected
20 h after the last dose by tail snip, and methemoglobin levels were estimated by using a
co-oximeter. Values are means SD of results for 5 animals in each group. NS, not
significantly different from results with the vehicle control.
FIG 3 Prophylactic antimalarial activities of ()- and ()-primaquine
against P. berghei in mice. Mice were inoculated with sporozoites on day 0.
Treatment with the drugs (p.o.) was daily on days1, 0, and 1.Mice normally
succumb to infection at about 1 week postinfection. The graph represents the
percentage of mice surviving to day 31 (study end). mpk, mg/kg.
TABLE 3 Oral efficacies of primaquine enantiomers and racemate
against pneumocystis infection in mice
Compound
Dose, mg/kg/day
(21 days)
Activity, no. cured/no.
treated (Giemsa stain)
Primaquine 10 5/10
5 0/10
2 0/10
()-Primaquine 10 9/10
5 3/10
2 0/10
()-Primaquine 10 0/10
5 0/10
2 0/10
TMP-SMX 50/250 9/10
NPC1161B 0.25 10/10
Control 0/10
Nanayakkara et al.
4740 aac.asm.org Antimicrobial Agents and Chemotherapy
mg/kg/day, administered over 21 days, ()-PQwas as active as the
TMP-SMX positive control at 50/250 mg/kg/day, with 9/10 mice
cleared of parasites. However, ()-PQ was without any effect at
the same dose level. The racemic PQ showed intermediate po-
tency, as expected, with 5/10mice cured at the 10-mg/kg/day dose
level.
Comparative general toxicity and methemoglobinemia in
beagle dogs. There was a striking difference in tolerability of PQ
enantiomers in beagle dogs. A previous preliminary study by our
group (N. P. D. Nanayakkara, J. D. McChesney, and A. M. Clark,
unpublished data) had shown that racemic PQ administered to
beagle dogs was well tolerated at 5 mg/kg/day for 4 days but elic-
itedmodestmethemoglobinemia, with females responding some-
what more thanmales. In the current study, treatment of 3 female
dogs with 4.86 mg/kg ()-PQ daily for 2 or 3 days resulted in
unexpected seriousmorbidity, with rises in aspartate aminotrans-
ferase, alanine aminotransferase, creatine kinase, and total biliru-
bin evident as early as day 2 and requiring suspension of dosing at
day 3 and termination of all animals by day 6. Methemoglobin
values moderately increased in a time-dependent manner (from
5.9%  1.7% pretreatment to 11.1%  0.5% at day 4) and then
returned toward the baseline level once dosing stopped. Decreases
in eosinophils and lymphocytes and increases in leukocytes, neu-
trophils, monocytes, and reticulocytes were also observed, but he-
moglobin/hematocrit values remained unchanged. Animals
treatedwith ()-PQconsistently lost bodyweight (16 to 17%over
6 days) until the time of moribund termination. These animals
also displayed lung damage at necropsy (discoloration and/or
firm/heavy lobes in 2/3 animals).
In contrast to the ()-PQ findings, all animals treated with
()-PQ at the same dose level (n 3) survived through the sched-
uled study period, with only incidental findings noted. The
()-PQ group showed only moderate weight loss over the course
of study days 1 to 8; the overall weight loss in the ()-PQ group
ranged from approximately 3 to 8%. All clinical chemistry and
hematological parameters for the ()-PQ-treated animals re-
mained comparable to baseline values through the end of the
study, although platelet counts appeared to be slightly decreased
by day 8.
Comparative hemolytic responses on G6PD-deficient hu-
man RBCs in SCID mice. To assess if there were differences in
hemolytic toxicities of the PQ enantiomers, NOD/SCID mice en-
grafted with huRBC from a G6PD-deficient donor were treated
with racemic PQ at a dose previously shown to induce hemolytic
toxicity in this model (12.5 mg/kg/day) (20) and with PQ enan-
tiomers at the same dose and at 6.25 mg/kg/day (Fig. 4). Treat-
ment with the ()-PQ enantiomer resulted in hemolytic toxicity
similar to that of racemic PQ, as indicated by the degree of loss of
huRBC after day 7 of treatment. In contrast, the levels of huRBC
for mice treated with the ()-PQ enantiomer were not signifi-
cantly different from those for themice given phosphate-buffered
saline (PBS) alone. The hemolytic response of ()-PQ was signif-
icantly higher than that of ()-PQ.
DISCUSSION
The importance of stereoisomerism inmodern drug development
is receiving increased attention, and considerations of differential
metabolism, pharmacokinetics, and/or pharmacodynamics of
pairs of stereoisomers are the general rule, not the exception.With
regard to antimalarial drugs, a number of prominent examples are
known (21). PQ is one such drug, developed more than 60 years
ago, when analytical and preparativemethodologies were limiting
and when the impact of enantiomeric differences was less well
recognized. Certainly in the modern era, it would be very difficult
to obtain regulatory approvals for a racemic drug candidate with-
out verification of similar metabolic fates and safety profiles of the
enantiomers.
Much effort has been devoted over the years to the study of PQ
in efforts to find approaches to delay its clearance and to under-
stand better the role of reactive metabolites in efficacy and toxic-
ity. In the course of these studies, a few laboratories, including
ours, have evaluated individual PQ enantiomers, though avail-
ability of these was somewhat limited (13–18). The metabolism
studies in rats revealed a greater stability of ()-PQ and more
rapid conversion of ()-PQ to the carboxyprimaquinemetabolite
(16–18). In an in vitro plasmodial tissue schizonticidal assay, the
() isomer was found to be equally active and slightly less cyto-
toxic than racemic PQ (14). In the same assay, ()-PQ was less
cytotoxic and less active than racemic PQ (14). Agarwal et al. (15)
reported more methemoglobin production and less membrane
leakiness for ()-PQ in human erythrocytes and the opposite for
the () isomer. However, the concentrations of PQ tested in these
studies (14, 15) were quite high, and the relevance of the findings
to the active metabolite species is unknown.
In the current study, we developed an efficient large-scale
method for preparation of the pure PQ enantiomers. Using these
two enantiomers, we confirmed and extended the findings on the
effects of PQ enantiomers in mice. Using two mouse models of
malaria (blood and exoerythrocytic stages), we found that
()-PQ was more potent than ()-PQ. Similar findings were
observed for Pneumocystis pneumonia in mice. The improved ac-
tivities we observed in mice for ()-(S)-PQ over those for the
()-(R)-form contrasted with that for the enantiomers of the
8-AQwith the 5-aryloxy substituent, NPC1161C (11). With these
enantiomers, ()-(R)-NPC1161B had better activity than ()-
(S)-NPC1161A for malaria and Pneumocystis pneumonia in
mousemodels (11). These findings raised the question of whether
FIG 4 Hemolytic toxicities of PQ enantiomers in NOD-SCID mice engrafted
with G6PD-deficient human erythrocytes. The data represent the loss of hu-
man erythrocytes onday 7 of treatment. Each bar represents themean values
SD from four animals. The data were analyzed by using the Student t test. P
values, PBS versus PQ (12.5), 	0.0001 (statistical significant difference [S]);
PBS versus ()-PQ (12.5), 0.003 (S); PBS versus ()-PQ (12.5), 0.05 (S); PBS
versus ()-PQ (6.25), 0.0004(S); PBS versus ()-PQ (6.25), 0.38 (difference
statistically not significant [NS]); PQ (12.5) versus ()-PQ12.5, 0.35 (NS); PQ
(12.5) versus ()-PQ (12.5), 0.0002 (S); ()-PQ (12.5) versus ()-PQ (12.5),
0.007 (S).
Pharmacologic Proﬁles of Primaquine Enantiomers
August 2014 Volume 58 Number 8 aac.asm.org 4741
the absolute configurations of ()-PQ and ()-NPC1161B are
both R. Previously, we determined the absolute configuration of
NPC1161A and NPC1161B by comparing their circular dichro-
ism (CD) spectra with those of ()-(S)-PQ and ()-(R)-PQ (see
Fig. S2a in the supplementalmaterial).We confirmed the absolute
configuration of ()-NPC1161A to be S by X-ray crystallography
of its (R)-()-phenylethylurea derivative (see Fig. S2b). This ob-
servation indicates that the absolute configurations of the respec-
tive ()-enantiomers of PQ and the analog are not different, but
some other structural feature dictates the divergence in the po-
tency profiles of their enantiomer pairs.
Even though the enantioselectivity for the antiparasitic activity
profile of primaquine enantiomers was opposite to that for
NPC1161C enantiomers, systemic toxicity profiles with mice for
enantiomers of PQ and NPC1161C were similar, where the ()-
(S)-enantiomer was more toxic. The systemic toxicity of ()-PQ
was 3- to 5-fold greater than that of ()-PQ. This was consistent
with what Schmidt reported in 1977 (13). In the same study,
Schmidt also reported that racemic PQ and enantiomers had
equivalent tissue schizonticidal activities against Plasmodium cyn-
omolgi in rhesus monkeys and that ()-PQ caused liver injury at
high doses. At the same dose, liver toxicity was much less promi-
nent with ()-PQ in monkeys. Schmidt proposed, based on the
primate findings, that ()-PQ might afford a safer alternative to
racemic PQ in humans (13).
An important consideration for the human application, how-
ever, is that the dose-limiting toxicity for PQ at dose levels cur-
rently employed is the hemolytic anemia elicited in G6PD-defi-
cient subjects (9, 10). Hepatotoxicity has not been reported as a
serious limitation for clinical use of PQ (2, 3). It is difficult to study
hemolytic effects of PQ in rodents and monkeys since they are
relatively insensitive to this toxicity. Three avenues of exploration
shed additional light on this. In the beagle dog, traditionally used
to study methemoglobin toxicity of 8-aminoquinolines, ()-PQ
showed severe systemic toxicity at the 5-mg/kg dose level, requir-
ing suspension of dosing and termination of administration after
the second daily dose. At this dose, ()-PQ caused a clear but
modest increase in methemoglobin by the second day, while
()-PQ had no effect even after 3 days of dosing.
We have recently developed a mouse model to study drug-
induced hemolysis of human G6PD-deficient RBCs (20). Using
NOD-SCID mice, it was demonstrated that PQ selectively de-
stroys erythrocytes engrafted from a G6PD-deficient but not
G6PD-normal human donors. In the present work, we used this
model to evaluate the differences in sensitivity to PQ enantiomers
and found that ()-PQ is about 3 timesmore hemolytic to human
G6PD-deficient RBCs in SCID mice. In other work (Saunders et
al., unpublished), our groups have confirmed Schmidt’s findings
that the two enantiomers were equally efficacious and ()-PQ
caused liver toxicity at higher doses in rhesus monkeys but also
extended these to show that ()-PQ more consistently generated
methemoglobinemia in this nonhuman primate. To the extent
that this reflects potential hemolytic toxicity, it would suggest that
()-PQ may have a therapeutic index advantage over the race-
mate in treatment of malaria in humans. Though ()-PQ gave
evidence of greater liver toxicity in the monkeys, this occurred
only at doses well above the therapeutic dose levels.
Activity and toxicity differences of PQ enantiomers can be at-
tributed to their different pharmacokinetic and metabolic pro-
files. PQ requires metabolic activation for its antiparasitic activity
and toxic effects (22).Deamination of the primary amino groupof
the side chain by monoamine oxidase (MOA) and hydroxylation
of the quinoline ring by CYP enzymes have been identified as the
twomajormetabolic pathways of PQ in in vitro (22, 23) and in vivo
(24) systems. Even though the aldehyde, the deamination product
of PQ by MOA, has not been detected, its oxidized product car-
boxyprimaquine has been identified as the major circulating me-
tabolite of racemic PQ in humans (25) and animals (26, 27). Bio-
logical studies have shown that carboxyprimaquine was inactive
(28) and nonhematotoxic (29). In contrast, ring-hydroxylated
metabolites of PQ generated by CYP enzymes (22, 23) can un-
dergo redox cycling, generating reactive oxygen species (ROS)
(30), which have been suggested to be responsible for antimalarial
activity (31) and hematotoxicity (29, 32). Various PQ ring-hy-
droxylated metabolites and their oxidized products produced by
CYP enzymes have been identified (22), and some of them have
been detected as minor metabolites in human liver microsomes
(33). Some of the hydroxylated PQ metabolites have been shown
to be active in vitro (34) and in vivo (28) and more hematotoxic
than the parent compound in in vitro assays (32, 34–36). Their
activity and toxicity have been linked to their superoxide genera-
tion capacity (34). If ROS are responsible for both activity and
hematotoxicity, the question remains whether it is possible for
one enantiomer to have a better therapeutic index than the race-
mate. Ring-hydroxy primaquine metabolites are generated by
CYP enzymes in the liver, where sporozoites (tissue schizonts) and
hypnozoites reside. For hematotoxicity to occur, they need to be
transported into erythrocytes. Of ring-hydroxylated metabolites,
5-hydroxyprimaquine has been suggested to be the major CYP-
mediatedmetabolite and has been shown to cause hematotoxicity
through generation of ROS (32, 35, 36). Synthetic 5-hydroxypri-
maquine was found to be unstable (35) and underwent spontane-
ous oxidation, leading to quinone-imine and its 6-demethyl
analog. Recovery studies we carried out have shown that 5-hy-
droxyprimaquine and its oxidized products irreversibly bound
to proteins (or other macromolecules), with resulting very low
recovery. Of other ring-hydroxylated metabolites which are capa-
ble of undergoing redox cycling, 7-hydroxy-primaquine is also
expected to be unstable, whereas synthetic 2- and 4-hydroxypri-
maquine were found to be stable (37, 38). Even though ring-
hydroxylated primaquines have been shown to cause hemato-
toxicity in vitro, their relative distribution in the liver and
erythrocytes has not been determined. There is also a possibility
that primaquine enters erythrocytes by diffusion and gets oxidized
to quinone imines or other redox-active species by ROS present
therein.
Metabolic studies have shown different metabolic rates and
profiles for primaquine enantiomers. The differential activity pro-
files we observed for PQ enantiomers in different animal models
may be due to their pharmacokinetic differences. Our studies (18)
in mice have shown that with administration of racemic PQ in
mice, ()-PQ had a shorter half-life (45 min) than ()-PQ (78
min). The inactive metabolite, carboxyprimaquine, rapidly ap-
pears in serum and is predominantly the () form. Thus, a signif-
icant portion of ()-PQ was rapidly converted to an inactive me-
tabolite, carboxyprimaquine, whereas ()-PQ was presumably
preferentially converted to ROS-generating ring-hydroxylated
products, although the fate of a majority of PQ was unaccounted
for (18). In other work (Saunders et al., unpublished), we ob-
served that in rhesus monkeys, ()-PQ had a somewhat longer
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half-life andmuch higherCmax and area under the concentration-
time curve (AUC) than ()-PQ; though ()-PQ was preferen-
tially converted to the carboxy metabolite compared to ()-PQ,
the differential was not as pronounced as that observed withmice.
Aftermore than 60 years of clinical use, uncertainties about PQ
metabolism and toxicity in humans remain. A key question is
whether the two enantiomers show differential therapeutic indi-
ces in humans.We have developed preliminary evidence (39) that
when the racemate was administered to healthy volunteers, there
was a dramatic difference in the conversion of the two enantiom-
ers to carboxyprimaquine, themajor circulatingmetabolite in hu-
mans (25), even though the serum concentrations of the enan-
tiomers were similar. As observed in other species, ()-PQ is
much more readily converted to the carboxylic acid form. How-
ever, since the profile and distribution of ring-hydroxylated me-
tabolites emanating from each enantiomer in the liver and eryth-
rocytes is not known, the relative toxicities and efficacies of the
two enantiomers in humans remain a mystery. Currently PQ is
administered at lower doses (15 mg/day) for long duration (14
days) as a precautionary measure to prevent hematotoxicity in
G6PD-deficient individuals (2, 3). Most of the treatment failures
of PQ have been attributed to lower dosage and poor compliance
(3). Even amodest improvement of the therapeutic index of PQby
selecting the enantiomer with better activity and toxicity profiles
would greatly enhance the therapeutic utility of this drug. A
“phase I”-type human study comparing the pharmacokinetics
and tolerability of PQ enantiomers would entail minimal risk and
potentially be a very informative study. From an ethical perspec-
tive, since individuals using PQ (in its currently available racemic
form) are routinely exposed to both enantiomers, if dosing is ini-
tiated at half of the clinically employed dose (30 or 45 mg of PQ
base), there would be little expectation of any untoward risk in
such a study. This would possibly afford a rapid path to an im-
proved liver-stage and gametocidal antimalarial drug (40) and
would in addition give guidance for future 8-aminoquinoline
drug development with respect to stereochemistry issues in hu-
mans.
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